Shattuck Labs (STTK) Net Cash Flow (2019 - 2026)
Shattuck Labs (STTK) posted quarterly Net Cash Flow of $36.2 million for Q1 2026, up 931.81% year-over-year from $3.5 million in Q1 2025, and up 211.12% quarter-over-quarter from $11.6 million in Q4 2025.
Analysis
Shattuck Labs (STTK) Net Cash Flow (2019 - 2026) Analysis & Trends
Shattuck Labs (STTK) has reported Net Cash Flow for 8 consecutive years, with $36.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 931.81% year-over-year to $36.2 million; the TTM figure through Mar 2026 stood at $29.5 million (up 295.41% YoY), while the FY2025 annual figure was -$3.2 million, up 95.32% from the prior year.
- Net Cash Flow rose to $36.2 million in Q1 2026 per STTK's latest filing, from $11.6 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $85.0 million in Q4 2023 and bottomed at -$49.6 million in Q1 2024.
- Historically, Net Cash Flow has averaged -$108764.7 across 5 years, with a median of $1.9 million in 2022.
- On a YoY basis, Net Cash Flow climbed as much as 1015.26% in 2023 and fell as far as 1755.77% in 2023.
- Shattuck Labs' Net Cash Flow stood at $7.6 million in 2022, then jumped by 1015.26% to $85.0 million in 2023, then tumbled by 84.05% to $13.6 million in 2024, then slipped by 14.12% to $11.6 million in 2025, then surged by 211.12% to $36.2 million in 2026.
- Business Quant data shows STTK's Net Cash Flow at $36.2 million in Q1 2026, $11.6 million in Q4 2025, and -$7.9 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -183.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 374.50 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 407.41 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -496,000.00 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 225.59 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Shattuck Labs | 885.09 Mn | 885.09 Mn | - | -27.12 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -27.12 Mn |
| Mar 31, 2026 | 36.23 Mn |
| Dec 31, 2025 | 11.64 Mn |
| Sep 30, 2025 | -7.92 Mn |
| Jun 30, 2025 | -10.43 Mn |
| Mar 31, 2025 | 3.51 Mn |
| Dec 31, 2024 | 13.56 Mn |
| Sep 30, 2024 | -16.86 Mn |
| Jun 30, 2024 | -15.31 Mn |
| Mar 31, 2024 | -49.62 Mn |
| Dec 31, 2023 | 84.99 Mn |
| Sep 30, 2023 | -31.26 Mn |
| Jun 30, 2023 | 5.85 Mn |
| Mar 31, 2023 | 18.66 Mn |
| Dec 31, 2022 | 7.62 Mn |
| Sep 30, 2022 | 1.89 Mn |
| Jun 30, 2022 | -12.87 Mn |
| Mar 31, 2022 | -41.53 Mn |
| Dec 31, 2021 | 7.17 Mn |
| Sep 30, 2021 | -1.40 Mn |